{"id":103114,"date":"2026-03-28T00:28:28","date_gmt":"2026-03-27T23:28:28","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=103114"},"modified":"2026-03-28T03:55:07","modified_gmt":"2026-03-28T02:55:07","slug":"jak-vase-posilujici-ockovani-proti-covid-19-ovlivnuje-vas-imunitni-system","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2026\/03\/28\/jak-vase-posilujici-ockovani-proti-covid-19-ovlivnuje-vas-imunitni-system\/","title":{"rendered":"Jak va\u0161e posiluj\u00edc\u00ed o\u010dkov\u00e1n\u00ed proti COVID-19 ovliv\u0148uje v\u00e1\u0161 imunitn\u00ed syst\u00e9m?"},"content":{"rendered":"
<\/div>\n
\n
\n

Snadno srozumiteln\u00fd pr\u016fvodce aktu\u00e1ln\u00edmi v\u00fdzkumn\u00fdmi poznatky<\/span><\/strong><\/p>\n

O co jde<\/span><\/strong><\/h3>\n

Pokud jste podstoupili n\u011bkolik posiluj\u00edc\u00edch d\u00e1vek proti COVID-19, stalo se s va\u0161\u00edm imunitn\u00edm syst\u00e9mem n\u011bco, o \u010dem se v\u00e1\u0161 l\u00e9ka\u0159 pravd\u011bpodobn\u011b nikdy nezm\u00ednil a co v\u00e1\u0161 krevn\u00ed test po o\u010dkov\u00e1n\u00ed t\u00e9m\u011b\u0159 jist\u011b nedok\u00e1\u017ee odhalit.<\/span><\/p>\n

Rostouc\u00ed po\u010det recenzovan\u00fdch v\u00fdzkum\u016f publikovan\u00fdch mezi lety 2023 a 2025 ukazuje, \u017ee opakovan\u00e9 posilovac\u00ed o\u010dkov\u00e1n\u00ed mRNA zp\u016fsobuje progresivn\u00ed posun v typech protil\u00e1tek, kter\u00e9 v\u00e1\u0161 imunitn\u00ed syst\u00e9m produkuje proti viru. Tento posun nen\u00ed n\u00e1hodn\u00fd \u0161um. Sleduje dob\u0159e pochopen\u00fd biologick\u00fd vzorec. A m\u00e1 m\u011b\u0159iteln\u00e9 funk\u010dn\u00ed d\u016fsledky.<\/span><\/p>\n

Tento \u010dl\u00e1nek vysv\u011btluje, o co v t\u00e9to zm\u011bn\u011b jde, co znamen\u00e1, pro koho je nejd\u016fle\u017eit\u011bj\u0161\u00ed a co by se s n\u00ed m\u011blo d\u011blat. Nejsou vy\u017eadov\u00e1ny \u017e\u00e1dn\u00e9 p\u0159edchoz\u00ed znalosti imunologie.<\/span><\/p>\n

Standardn\u00ed krevn\u00ed test po o\u010dkov\u00e1n\u00ed, kter\u00fd odhal\u00ed, kolik protil\u00e1tek m\u00e1te, v\u00e1m ne\u0159ekne, o jak\u00fd typ protil\u00e1tek se jedn\u00e1. Toto rozli\u0161en\u00ed se v\u0161ak st\u00e1v\u00e1 d\u016fle\u017eit\u00fdm po n\u011bkolika posilovac\u00edch o\u010dkov\u00e1n\u00edch.<\/span><\/em><\/p>\n

Ne v\u0161echny protil\u00e1tky jsou stejn\u00e9<\/span><\/strong><\/h3>\n
\"\"<\/figure>\n

Va\u0161e t\u011blo produkuje r\u016fzn\u00e9 typy protil\u00e1tek, zn\u00e1m\u00e9 jako IgG1 a\u017e IgG4. Kdy\u017e se poprv\u00e9 setk\u00e1te s virem nebo dostanete o\u010dkov\u00e1n\u00ed, v\u00e1\u0161 imunitn\u00ed syst\u00e9m produkuje prim\u00e1rn\u011b IgG1 a IgG3. Jsou to va\u0161e \u201ebojov\u00e9\u201c protil\u00e1tky. Pln\u00ed dv\u011b d\u016fle\u017eit\u00e9 funkce:<\/span><\/p>\n

\u2022 Zabra\u0148uj\u00ed viru vniknout do bun\u011bk (to se naz\u00fdv\u00e1 neutralizace).<\/span><\/p>\n

\u2022 Rekrutuj\u00ed dal\u0161\u00ed imunitn\u00ed bu\u0148ky k detekci a ni\u010den\u00ed bun\u011bk ji\u017e infikovan\u00fdch virem. Tato druh\u00e1 funkce se naz\u00fdv\u00e1 ADCC (protil\u00e1tkov\u011b z\u00e1visl\u00e1 bun\u011b\u010dn\u00e1 cytotoxicita) a z\u00e1vis\u00ed na \u010d\u00e1sti protil\u00e1tky zn\u00e1m\u00e9 jako Fc oblast.<\/span><\/p>\n

IgG4 je jin\u00fd. N\u011bkdy se mu \u0159\u00edk\u00e1 toleran\u010dn\u00ed protil\u00e1tka. V ka\u017edodenn\u00edm \u017eivot\u011b je p\u0159\u00edtomen v mal\u00e9m mno\u017estv\u00ed, v\u011bt\u0161inou v situac\u00edch, kdy v\u00e1\u0161 imunitn\u00ed syst\u00e9m opakovan\u011b p\u0159i\u0161el do kontaktu s n\u011b\u010d\u00edm a rozhodl se, \u017ee to nep\u0159edstavuje \u017e\u00e1dnou hrozbu, nap\u0159\u00edklad s v\u010del\u00edm jedem pro v\u010dela\u0159e nebo s alergeny pro lidi podstupuj\u00edc\u00ed imunoterapii. IgG4 dok\u00e1\u017ee neutralizovat virus, ale nem\u016f\u017ee prov\u00e1d\u011bt ADCC, aktivovat syst\u00e9m komplementu (dal\u0161\u00ed sou\u010d\u00e1st imunitn\u00ed obrany) ani se v\u00e1zat na receptory na imunitn\u00edch bu\u0148k\u00e1ch, kter\u00e9 rekrutuj\u00ed dal\u0161\u00ed imunitn\u00ed bu\u0148ky k eliminaci infikovan\u00e9 bu\u0148ky.<\/span><\/p>\n

Jin\u00fdmi slovy, IgG4 je blokuj\u00edc\u00ed protil\u00e1tka. Rozpozn\u00e1v\u00e1 virus a blokuje ho, ale ned\u00e1v\u00e1 zbytku imunitn\u00edho syst\u00e9mu sign\u00e1l k \u00fatoku.<\/span><\/p>\n

IgG4 neutralizuje virus. Neodstra\u0148uje v\u0161ak infikovan\u00e9 bu\u0148ky, neaktivuje syst\u00e9m komplementu ani nerekrutuje imunitn\u00ed bu\u0148ky. Nejedn\u00e1 se o ekvivalentn\u00ed procesy.<\/span><\/em><\/p>\n

Co opakovan\u00e9 \u201epos\u00edlen\u00ed\u201c d\u011bl\u00e1 s touto rovnov\u00e1hou<\/span><\/strong><\/h3>\n
\"\"<\/figure>\n

Po prvn\u00edch dvou o\u010dkov\u00e1n\u00edch proti COVIDu v\u00e1\u0161 imunitn\u00ed syst\u00e9m produkuje prim\u00e1rn\u011b IgG1 a IgG3. Tot\u00e9\u017e plat\u00ed po p\u0159irozen\u00e9 infekci. Jedn\u00e1 se o norm\u00e1ln\u00ed a o\u010dek\u00e1vanou reakci.<\/span><\/p>\n

Nicm\u00e9n\u011b po t\u0159et\u00ed d\u00e1vce \u2013 a v n\u011bkter\u00fdch p\u0159\u00edpadech i po druh\u00e9 \u2013 se n\u011bco zm\u011bn\u00ed a tento \u00fa\u010dinek se s ka\u017edou dal\u0161\u00ed d\u00e1vkou zesiluje. N\u011bkolik recenzovan\u00fdch studi\u00ed nyn\u00ed ukazuje, \u017ee opakovan\u00e9 posilovac\u00ed o\u010dkov\u00e1n\u00ed mRNA zp\u016fsobuje progresivn\u00ed posun sm\u011brem k IgG4 v protil\u00e1tkov\u00e9 odpov\u011bdi, konkr\u00e9tn\u011b zam\u011b\u0159en\u00e9 na spike protein. Tento posun:<\/span><\/p>\n

\u2022 Neobjevuje se pouze po p\u0159irozen\u00e9 infekci.<\/span><\/p>\n

\u2022 Nevyskytuje se po vakc\u00edn\u00e1ch na b\u00e1zi vektor\u016f s obsahem adenoviru (jako je AstraZeneca nebo Johnson & Johnson).<\/span><\/p>\n

\u2022 Je v\u00fdrazn\u011bj\u0161\u00ed u vakc\u00edny Pfizer ne\u017e u vakc\u00edny Moderna.<\/span><\/p>\n

\u2022 Zdokumentov\u00e1no u d\u011bt\u00ed ji\u017e od 5 let po pouh\u00fdch dvou pediatrick\u00fdch d\u00e1vk\u00e1ch.<\/span><\/p>\n

Studie z roku 2025 (Kalkeri a kol., Journal of Infectious Diseases) poskytla prvn\u00ed p\u0159\u00edm\u00fd funk\u010dn\u00ed d\u016fkaz o cen\u011b t\u00e9to zm\u011bny. V\u011bdci zjistili, \u017ee vy\u0161\u0161\u00ed hladiny IgG4 negativn\u011b korelovaly se schopnost\u00ed neutralizovat virus a se v\u0161emi t\u0159emi m\u011b\u0159en\u00fdmi imunitn\u00edmi efektorov\u00fdmi funkcemi (bun\u011b\u010dn\u00e9 a molekul\u00e1rn\u00ed procesy, kter\u00e9 eliminuj\u00ed infikovan\u00e9 bu\u0148ky). Jedinci, kte\u0159\u00ed dostali mRNA vakc\u00edny, m\u011bli v\u00edce ne\u017e 150kr\u00e1t vy\u0161\u0161\u00ed hladiny IgG4 ne\u017e ti, kte\u0159\u00ed dostali proteinovou podjednotkovou vakc\u00ednu. Pozn\u00e1mka: Tuto studii financovala spole\u010dnost Novavax, v\u00fdrobce proteinov\u00fdch podjednotkov\u00fdch vakc\u00edn, a v\u011bt\u0161ina jej\u00edch autor\u016f pracuje pro Novavax. St\u0159et z\u00e1jm\u016f je skute\u010dn\u00fd a m\u011bl by b\u00fdt zv\u00e1\u017een. Zji\u0161t\u011bn\u00ed jsou tak\u00e9 v souladu s dal\u0161\u00edm nez\u00e1visl\u00fdm v\u00fdzkumem.<\/span><\/p>\n

Samostatn\u00e1 studie z roku 2025 (Mart\u00edn P\u00e9rez a kol., Journal of Infection) zjistila, \u017ee zdravotni\u010dt\u00ed pracovn\u00edci, u kter\u00fdch do\u0161lo k tomuto posunu IgG4, m\u011bli vy\u0161\u0161\u00ed pravd\u011bpodobnost n\u00e1sledn\u00fdch infekc\u00ed COVID-19. Jedn\u00e1 se o prvn\u00ed publikovanou studii, kter\u00e1 spojuje posun IgG4 se skute\u010dn\u00fdm negativn\u00edm zdravotn\u00edm v\u00fdsledkem. I kdy\u017e je to je\u0161t\u011b t\u0159eba potvrdit ve v\u011bt\u0161\u00edch studi\u00edch, sm\u011br v\u00fdsledk\u016f je p\u0159esn\u011b v souladu s biologick\u00fdmi o\u010dek\u00e1v\u00e1n\u00edmi.<\/span><\/p>\n

Pro\u010d opakovan\u00e9 posilovac\u00ed o\u010dkov\u00e1n\u00ed zp\u016fsobuje toto zpo\u017ed\u011bn\u00ed<\/span><\/strong><\/h3>\n

V\u00e1\u0161 imunitn\u00ed syst\u00e9m se u\u010d\u00ed opakov\u00e1n\u00edm. Pokud se opakovan\u011b setk\u00e1v\u00e1 se stejn\u00fdm antigenem (v tomto p\u0159\u00edpad\u011b s proteinem spike) v relativn\u011b klidn\u00e9m prost\u0159ed\u00ed, postupn\u011b tento antigen klasifikuje jako perzistentn\u00ed, ale neohro\u017euj\u00edc\u00ed p\u0159\u00edtomnost a p\u0159esouv\u00e1 svou reakci sm\u011brem k toleranci sp\u00ed\u0161e ne\u017e k \u00fatoku. To je ve skute\u010dnosti u\u017eite\u010dn\u00e1 vlastnost v ka\u017edodenn\u00edm \u017eivot\u011b. Je to stejn\u00fd mechanismus, kter\u00fd umo\u017e\u0148uje v\u010dela\u0159\u016fm st\u00e1t se imunn\u00edmi v\u016f\u010di bodnut\u00ed v\u010delou a kter\u00fd \u010din\u00ed imunoterapii \u00fa\u010dinnou p\u0159i alergi\u00edch.<\/span><\/p>\n

Tuto zm\u011bnu \u0159\u00edd\u00ed molekula zvan\u00e1 IL-10, chemick\u00fd sign\u00e1l produkovan\u00fd v lymfatick\u00fdch uzlin\u00e1ch b\u011bhem imunitn\u00ed odpov\u011bdi. IL-10 p\u016fsob\u00ed lok\u00e1ln\u011b v z\u00e1rode\u010dn\u00fdch centrech, kde se navrhuj\u00ed a zdokonaluj\u00ed nov\u00e9 protil\u00e1tky. Pokud je IL-10 p\u0159\u00edtomen v tomto lok\u00e1ln\u00edm prost\u0159ed\u00ed, imunitn\u00ed bu\u0148ky jsou indukov\u00e1ny k produkci IgG4 m\u00edsto IgG1 nebo IgG3.<\/span><\/p>\n

D\u016fle\u017eit\u00e9 up\u0159esn\u011bn\u00ed: Nejedn\u00e1 se o obecnou imunosupresi<\/span><\/strong><\/h3>\n

Mo\u017en\u00e1 jste \u010detli tvrzen\u00ed, \u017ee posiluj\u00edc\u00ed d\u00e1vky proti COVIDu celkov\u011b potla\u010duj\u00ed imunitn\u00ed syst\u00e9m zv\u00fd\u0161en\u00edm hladiny IL-10. Toto tvrzen\u00ed v\u0161ak nen\u00ed podlo\u017eeno d\u016fkazy. Mno\u017estv\u00ed IL-10 produkovan\u00e9 vakc\u00ednou se pohybuje v rozmez\u00ed n\u00edzk\u00fdch pikogram\u016f na mililitr \u2013 jde o nepatrn\u00e1 mno\u017estv\u00ed, kter\u00e1 se rychle odbour\u00e1vaj\u00ed. Koncentrace pot\u0159ebn\u00e9 k potla\u010den\u00ed NK bun\u011bk, zhor\u0161en\u00ed odpov\u011bd\u00ed T bun\u011bk nebo vyvol\u00e1n\u00ed imunodeficience pozorovan\u00e9 u pacient\u016f s rakovinou jsou tis\u00edckr\u00e1t vy\u0161\u0161\u00ed ne\u017e koncentrace produkovan\u00e9 vakc\u00ednou.<\/span><\/p>\n

Skute\u010dn\u00fdm probl\u00e9mem nen\u00ed syst\u00e9mov\u00e1 imunosuprese. Jde o c\u00edlen\u00e9, lok\u00e1ln\u00ed p\u0159eprogramov\u00e1n\u00ed mechanismu produkce protil\u00e1tek v lymfatick\u00fdch uzlin\u00e1ch. Tento rozd\u00edl je kl\u00ed\u010dov\u00fd: komplexn\u00ed potla\u010den\u00ed by bylo do\u010dasn\u00e9 a reverzibiln\u00ed. Tyto lok\u00e1ln\u00ed \u00fa\u010dinky na lymfatick\u00e9 uzliny mohou ovlivnit imunitn\u00ed odpov\u011bdi na spike antigen i na dal\u0161\u00ed antigeny prezentovan\u00e9 ve stejn\u00e9 lymfatick\u00e9 uzlin\u011b. V\u00fdzkum dokumentuje, \u017ee se li\u0161\u00ed od syst\u00e9mov\u00e9 imunosuprese. Je zak\u00f3dov\u00e1na v imunitn\u00ed pam\u011bti a prob\u00edh\u00e1 na \u00farovni jednotliv\u00fdch lymfatick\u00fdch uzlin.<\/span><\/p>\n

\"\"<\/figure>\n
\"\"<\/figure>\n
\"\"<\/figure>\n

Probl\u00e9m s pam\u011bt\u00ed<\/span><\/strong><\/h3>\n

Jakmile se v z\u00e1rode\u010dn\u00fdch centrech vytvo\u0159\u00ed imunitn\u00ed bu\u0148ky produkuj\u00edc\u00ed IgG4, trvale se usad\u00ed v kostn\u00ed d\u0159eni jako dlouhov\u011bk\u00e9 plazmatick\u00e9 bu\u0148ky. IgG4 produkuj\u00ed i \u200b\u200bnad\u00e1le po cel\u00e1 l\u00e9ta. Nelze je deaktivovat \u010dek\u00e1n\u00edm a jejich aktivitu nelze zvr\u00e1tit ukon\u010den\u00edm o\u010dkov\u00e1n\u00ed. Jak\u00e1koli dal\u0161\u00ed expozice spike proteinu (nebo jin\u00fdm antigen\u016fm, kter\u00e9 vyvolaly podobn\u00e9 reakce v ur\u010dit\u00fdch lymfatick\u00fdch uzlin\u00e1ch), a\u0165 u\u017e prost\u0159ednictv\u00edm posilovac\u00ed d\u00e1vky o\u010dkov\u00e1n\u00ed nebo skute\u010dn\u00e9 infekce, zp\u016fsob\u00ed, \u017ee tyto bu\u0148ky produkuj\u00ed v\u00edce IgG4.<\/span><\/p>\n

D\u00e1le studie z roku 2024 (Kim, Immune Networks) shrnula d\u016fkazy o tom, \u017ee vakcina\u010dn\u00ed platforma mRNA-LNP vyvol\u00e1v\u00e1 neobvykle dlouhotrvaj\u00edc\u00ed imunitn\u00ed odpov\u011bdi v lymfatick\u00fdch uzlin\u00e1ch, kter\u00e9 trvaj\u00ed \u0161est m\u011bs\u00edc\u016f nebo d\u00e9le. Tato prodlou\u017een\u00e1 aktivita umo\u017e\u0148uje ka\u017ed\u00e9 posilovac\u00ed d\u00e1vce d\u00e1le pos\u00edlit vzorec IgG4 v pam\u011bti imunitn\u00edho syst\u00e9mu. Stejn\u00e1 vlastnost, kter\u00e1 \u010din\u00ed mRNA vakc\u00edny tak imunologicky \u00fa\u010dinn\u00fdmi, je z\u00e1rove\u0148 \u010din\u00ed struktur\u00e1ln\u011b n\u00e1chyln\u00fdmi k tomuto \u00fa\u010dinku p\u0159i \u010dast\u00e9m pod\u00e1v\u00e1n\u00ed.<\/span><\/p>\n

Pro\u010d je d\u016fle\u017eit\u00fd interval mezi posilovac\u00edmi o\u010dkov\u00e1n\u00edmi<\/span><\/h3>\n
\"\"<\/figure>\n

Pokud se posilovac\u00ed d\u00e1vky pod\u00e1vaj\u00ed p\u0159ed \u00fapln\u00fdm odezn\u011bn\u00edm imunitn\u00ed odpov\u011bdi na p\u0159edchoz\u00ed d\u00e1vku, sign\u00e1ly se p\u0159ekr\u00fdvaj\u00ed a vz\u00e1jemn\u011b se posiluj\u00ed. Tento proces je zn\u00e1m\u00fd jako \u201eskl\u00e1d\u00e1n\u00ed sign\u00e1l\u016f\u201c. Ka\u017ed\u00e1 p\u0159ekr\u00fdvaj\u00edc\u00ed se d\u00e1vka posiluje regula\u010dn\u00ed prost\u0159ed\u00ed IL-10 a d\u00e1le podporuje posun IgG4. D\u00edky posilovac\u00edm d\u00e1vk\u00e1m podan\u00fdm s odstupem alespo\u0148 jednoho roku m\u016f\u017ee imunitn\u00ed odpov\u011b\u010f zcela odezn\u00edt a resetovat se p\u0159ed op\u011btovnou expozic\u00ed, \u010d\u00edm\u017e se sni\u017euje pravd\u011bpodobnost posunu IgG4.<\/span><\/p>\n

Co v\u00fdzkum odhalil: zn\u00e1m\u00e9 a potenci\u00e1ln\u00ed \u0161kody<\/span><\/strong><\/h3>\n
\"\"<\/figure>\n

Tato anal\u00fdza rozd\u011bluje zji\u0161t\u011bn\u00ed o ne\u017e\u00e1douc\u00edch \u00fa\u010dinc\u00edch do dvou kategori\u00ed: ty, kter\u00e9 jsou dokumentov\u00e1ny publikovan\u00fdmi d\u016fkazy, a ty, kter\u00e9 jsou biologicky pravd\u011bpodobn\u00e9, ale dosud nebyly potvrzeny ve studi\u00edch velk\u00e9ho rozsahu.<\/span><\/p>\n

Co je zdokumentov\u00e1no<\/span><\/strong><\/h3>\n

1. Zv\u00fd\u0161en\u00e9 riziko pr\u016flomov\u00e9 n\u00e1kazy COVID-19<\/span><\/strong><\/p>\n

Mart\u00edn P\u00e9rez a kol. (2025) zjistili, \u017ee zdravotni\u010dt\u00ed pracovn\u00edci, u kter\u00fdch se vyvinul posun IgG4, m\u011bli n\u00e1sledn\u011b vy\u0161\u0161\u00ed pravd\u011bpodobnost n\u00e1kazy COVID-19. Toto je prvn\u00ed publikovan\u00e1 studie, kter\u00e1 spojuje posun protil\u00e1tek se skute\u010dn\u00fdm negativn\u00edm zdravotn\u00edm v\u00fdsledkem. Studie je st\u00e1le t\u0159eba ji replikovat, ale sm\u011br lze biologicky p\u0159edpov\u011bd\u011bt.<\/span><\/p>\n

2. Ztr\u00e1ta imunitn\u00edch funkc\u00ed, kter\u00e9 eliminuj\u00ed infikovan\u00e9 bu\u0148ky<\/span><\/strong><\/p>\n

Kalkeri a kol. (2025) p\u0159\u00edmo m\u011b\u0159ili funk\u010dn\u00ed d\u016fsledky. Vy\u0161\u0161\u00ed hladiny IgG4 korelovaly se sn\u00ed\u017een\u00fdm v\u00fdkonem ve t\u0159ech r\u016fzn\u00fdch mechanismech imunitn\u00ed obrany: ADCC (r = \u20130,53), ukl\u00e1d\u00e1n\u00ed komplementu (r = \u20130,53) a fagocyt\u00f3za (r = \u20130,40). Nejedn\u00e1 se o teorie; jedn\u00e1 se o publikovan\u00e1 m\u011b\u0159en\u00ed.<\/span><\/p>\n

3. Po\u0161kozen\u00ed je ulo\u017eeno v imunitn\u00ed pam\u011bti.<\/span><\/strong><\/p>\n

Irrgang a kol. (Science Immunology, 2023) zjistili, \u017ee 14,4 % bun\u011bk dlouhodob\u00e9 imunopam\u011bti nam\u00ed\u0159en\u00fdch proti spike proteinu produkovalo IgG4 po opakovan\u00fdch posilovac\u00edch d\u00e1vk\u00e1ch. Tyto bu\u0148ky p\u0159etrv\u00e1vaj\u00ed po cel\u00e9 roky. Po\u0161kozen\u00ed nezmiz\u00ed po ukon\u010den\u00ed o\u010dkov\u00e1n\u00ed.<\/span><\/p>\n

4. D\u011bti jsou tak\u00e9 posti\u017eeny<\/span><\/strong><\/p>\n

Kobbe a kol. (Pediatric Infectious Disease Journal, 2024) potvrdili zm\u011bnu IgG4 u d\u011bt\u00ed ve v\u011bku 5 a\u017e 11 let po pouh\u00fdch dvou d\u00e1vk\u00e1ch standardn\u00ed pediatrick\u00e9 vakc\u00edny. Tento \u00fa\u010dinek se neomezuje pouze na dosp\u011bl\u00e9, kte\u0159\u00ed dostali mnoho posilovac\u00edch o\u010dkov\u00e1n\u00ed.<\/span><\/p>\n

Co\u017e je sice pravd\u011bpodobn\u00e9, ale zat\u00edm to nebylo potvrzeno<\/span><\/strong><\/h3>\n
\"\"<\/figure>\n

N\u00e1sleduj\u00edc\u00ed rizika nebyla potvrzena ve velk\u00fdch studi\u00edch. Jsou zm\u00edn\u011bna, proto\u017ee biologick\u00fd mechanismus je zn\u00e1m\u00fd a jsou p\u0159\u00edtomny podm\u00ednky pro po\u0161kozen\u00ed. Nedostatek potvrzen\u00ed v tomto p\u0159\u00edpad\u011b znamen\u00e1, \u017ee nebyly provedeny \u017e\u00e1dn\u00e9 relevantn\u00ed studie, ale neznamen\u00e1, \u017ee jsou rizika vylou\u010dena.<\/span><\/p>\n

\u2022\u00a0<\/span>Onemocn\u011bn\u00ed asociovan\u00e9 s IgG4 (IgG4-RD).<\/span><\/strong>\u00a0Vz\u00e1cn\u00e9 z\u00e1n\u011btliv\u00e9 onemocn\u011bn\u00ed postihuj\u00edc\u00ed slinivku b\u0159i\u0161n\u00ed, ledviny, slinn\u00e9 \u017el\u00e1zy a dal\u0161\u00ed org\u00e1ny, vyvolan\u00e9 stejn\u00fdm imunitn\u00edm prost\u0159ed\u00edm, kter\u00e9 je zes\u00edleno opakovan\u00fdmi posilovac\u00edmi d\u00e1vkami. Existuj\u00ed hl\u00e1\u0161en\u00ed o nov\u011b vznikl\u00e9m nebo zhor\u0161uj\u00edc\u00edm se IgG4-RD po o\u010dkov\u00e1n\u00ed proti COVID-19. Systematick\u00fd dohled nebyl proveden.<\/span><\/p>\n

\u2022\u00a0<\/span>Zhor\u0161en\u00fd imunitn\u00ed dohled u rakoviny.<\/span><\/strong>\u00a0Imunitn\u00ed syst\u00e9m \u010d\u00e1ste\u010dn\u011b ni\u010d\u00ed ran\u00e9 rakovinn\u00e9 bu\u0148ky prost\u0159ednictv\u00edm ADCC. Pokud je kapacita ADCC sn\u00ed\u017eena, m\u016f\u017ee b\u00fdt naru\u0161ena schopnost t\u011bla zachytit a eliminovat abnorm\u00e1ln\u00ed bu\u0148ky d\u0159\u00edve, ne\u017e se z nich stanou n\u00e1dory. To je zvl\u00e1\u0161t\u011b d\u016fle\u017eit\u00e9 pro pacienty, kte\u0159\u00ed podstupuj\u00ed imunoterapii proti rakovin\u011b, jako je rituximab nebo trastuzumab, kter\u00e9 se spol\u00e9haj\u00ed na stejn\u00fd mechanismus.<\/span><\/p>\n

\u2022\u00a0<\/span>Zhor\u0161en\u00ed l\u00e9\u010dby rakoviny.<\/span><\/strong>\u00a0Vysok\u00e9 koncentrace IgG4 v krevn\u00edm \u0159e\u010di\u0161ti mohou konkurovat terapeutick\u00fdm protil\u00e1tk\u00e1m o m\u00edsta Fc receptor\u016f na imunitn\u00edch bu\u0148k\u00e1ch a mohou sni\u017eovat \u00fa\u010dinnost protin\u00e1dorov\u00fdch l\u00e9k\u016f z\u00e1visl\u00fdch na ADCC u pacient\u016f, kte\u0159\u00ed b\u011bhem l\u00e9\u010dby dostali posilovac\u00ed d\u00e1vku.<\/span><\/p>\n

\u2022\u00a0<\/span>Oslaben\u00e1 reakce na jin\u00e9 vakc\u00edny a infekce.<\/span><\/strong>\u00a0Zv\u00fd\u0161en\u00fd po\u010det regula\u010dn\u00edch B bun\u011bk v d\u016fsledku opakovan\u00fdch posilovac\u00edch d\u00e1vek tak\u00e9 potla\u010duje imunitn\u00ed reakce v \u0161ir\u0161\u00edm smyslu. Zda to sni\u017euje \u00fa\u010dinnost vakc\u00edn proti ch\u0159ipce, vakc\u00edn proti z\u00e1palu plic nebo jin\u00fdch b\u011b\u017en\u011b pod\u00e1van\u00fdch vakc\u00edn sou\u010dasn\u011b, dosud nebylo zkoum\u00e1no.<\/span><\/p>\n

\u2022\u00a0<\/span>Imunologick\u00fd imprinting.<\/span><\/strong>\u00a0Imunitn\u00ed bu\u0148ky produkovan\u00e9 po\u010d\u00e1te\u010dn\u00edm o\u010dkov\u00e1n\u00edm dominuj\u00ed budouc\u00edm reakc\u00edm a vytla\u010duj\u00ed bu\u0148ky, kter\u00e9 by reagovaly na nov\u00e9 varianty. To znamen\u00e1, \u017ee opakovan\u00e9 posilovac\u00ed o\u010dkov\u00e1n\u00ed by mohlo st\u00e1le v\u00edce zhor\u0161ovat schopnost va\u0161eho imunitn\u00edho syst\u00e9mu vyvinout novou reakci na v\u00fdrazn\u011b odli\u0161n\u00fd budouc\u00ed virus.<\/span><\/p>\n

\u2022\u00a0<\/span>Tvorba autoprotil\u00e1tek.<\/span><\/strong>\u00a0Spike protein vykazuje struktur\u00e1ln\u00ed podobnosti s n\u011bkter\u00fdmi lidsk\u00fdmi proteiny. Zv\u00fd\u0161en\u00e9 m\u00edry mutac\u00ed dokumentovan\u00e9 v imunitn\u00edch odpov\u011bd\u00edch zprost\u0159edkovan\u00fdch mRNA vytv\u00e1\u0159ej\u00ed podm\u00ednky pro zk\u0159\u00ed\u017een\u011b reaguj\u00edc\u00ed protil\u00e1tky, kter\u00e9 mohou c\u00edlit na vlastn\u00ed tk\u00e1\u0148 t\u011bla. Toto dosud nebylo systematicky zkoum\u00e1no.<\/span><\/p>\n

Nedostatek \u00fadaj\u016f o t\u011bchto tras\u00e1ch neznamen\u00e1, \u017ee neexistuj\u00ed. Znamen\u00e1 to jednodu\u0161e, \u017ee je nikdo nehledal. Syst\u00e9m sledov\u00e1n\u00ed nebyl navr\u017een tak, aby je detekoval.<\/span><\/em><\/p>\n

Pro koho je to d\u016fle\u017eit\u00e9 a pro\u010d<\/span><\/strong><\/h3>\n
\"\"<\/figure>\n

Nejd\u016fle\u017eit\u011bj\u0161\u00edm bodem cel\u00e9ho tohoto \u010dl\u00e1nku je, \u017ee stejn\u00fd posun v imunit\u011b m\u016f\u017ee m\u00edt zcela odli\u0161n\u00e9 \u00fa\u010dinky v z\u00e1vislosti na tom, kdo jste.<\/span><\/p>\n

Vysoce rizikov\u00ed dosp\u011bl\u00ed: star\u0161\u00ed lid\u00e9, osoby s oslabenou imunitou, osoby se z\u00e1va\u017en\u00fdmi chronick\u00fdmi onemocn\u011bn\u00edmi<\/span><\/strong><\/h3>\n

Pro osoby, kter\u00e9 jsou skute\u010dn\u011b vystaveny vysok\u00e9mu riziku t\u011b\u017ek\u00e9ho pr\u016fb\u011bhu onemocn\u011bn\u00ed COVID-19, jsou opakovan\u00e1 posilovac\u00ed o\u010dkov\u00e1n\u00ed pravd\u011bpodobn\u011b st\u00e1le tou spr\u00e1vnou volbou. COVID-19 zab\u00edj\u00ed prim\u00e1rn\u011b nadm\u011brn\u00fdm z\u00e1n\u011btem, nikoli p\u0159\u00edm\u00fdm po\u0161kozen\u00edm virem. Posun IgG4, kter\u00fd tlum\u00ed tuto z\u00e1n\u011btlivou reakci a z\u00e1rove\u0148 si zachov\u00e1v\u00e1 schopnost neutralizovat virus, by skute\u010dn\u011b mohl nab\u00eddnout ochranu lidem, jejich\u017e nejv\u011bt\u0161\u00edm rizikem je p\u0159ehnan\u00e1 reakce jejich t\u011bla. Zdokumentovan\u00fd p\u0159\u00ednos o\u010dkov\u00e1n\u00ed proti t\u011b\u017ek\u00e9mu onemocn\u011bn\u00ed a \u00famrt\u00ed v t\u00e9to skupin\u011b je skute\u010dn\u00fd.<\/span><\/p>\n

Samotn\u00e1 zji\u0161t\u011bn\u00ed u t\u00e9to skupiny v\u0161ak nazna\u010duj\u00ed, \u017ee posilovac\u00ed o\u010dkov\u00e1n\u00ed by m\u011blo b\u00fdt prov\u00e1d\u011bno v intervalech alespo\u0148 jednoho roku, m\u011bly by b\u00fdt zv\u00e1\u017eeny ni\u017e\u0161\u00ed d\u00e1vky a p\u0159\u00edpadn\u011b by m\u011bla b\u00fdt pro posilovac\u00ed d\u00e1vku pou\u017eita vakc\u00edna s proteinovou podjednotkou (nap\u0159\u00edklad Novavax), aby se zabr\u00e1nilo amplifikaci posunu IgG4.<\/span><\/p>\n

Zdrav\u00ed dosp\u011bl\u00ed a mlad\u00ed lid\u00e9<\/span><\/strong><\/h3>\n

U zdrav\u00fdch dosp\u011bl\u00fdch, kte\u0159\u00ed nejsou vystaveni zv\u00fd\u0161en\u00e9mu riziku z\u00e1va\u017en\u00e9ho pr\u016fb\u011bhu COVID-19, je v\u00fdpo\u010det jin\u00fd. Individu\u00e1ln\u00ed riziko z\u00e1va\u017en\u00e9ho onemocn\u011bn\u00ed je velmi n\u00edzk\u00e9. P\u0159\u00ednos dal\u0161\u00edch posilovac\u00edch o\u010dkov\u00e1n\u00ed je v absolutn\u00edch \u010d\u00edslech mal\u00fd. A ne\u017e\u00e1douc\u00ed imunitn\u00ed ud\u00e1losti zde zdokumentovan\u00e9 (ztr\u00e1ta funkce clearance Fc, perzistuj\u00edc\u00ed pam\u011b\u0165ov\u00e9 k\u00f3dov\u00e1n\u00ed IgG4, imunologick\u00fd imprinting) nejsou vyv\u00e1\u017eeny \u017e\u00e1dn\u00fdm odpov\u00eddaj\u00edc\u00edm p\u0159\u00ednosem. L\u00e9ka\u0159i, kte\u0159\u00ed t\u00e9to skupin\u011b rad\u00ed, jsou povinni tyto \u00favahy vysv\u011btlit a neprezentovat pokra\u010dov\u00e1n\u00ed v posilovac\u00edm o\u010dkov\u00e1n\u00ed jako zjevn\u011b v\u00fdhodn\u00e9.<\/span><\/p>\n

D\u011bti<\/span><\/strong><\/h3>\n

V\u00fdsledky u d\u011bt\u00ed jsou obzvl\u00e1\u0161t\u011b znepokojiv\u00e9. D\u011bti maj\u00ed prakticky nulov\u00e9 individu\u00e1ln\u00ed riziko t\u011b\u017ek\u00e9ho pr\u016fb\u011bhu onemocn\u011bn\u00ed COVID-19. Zdokumentovan\u00e9 od\u016fvodn\u011bn\u00ed jejich o\u010dkov\u00e1n\u00ed bylo zalo\u017eeno t\u00e9m\u011b\u0159 v\u00fdhradn\u011b na sn\u00ed\u017een\u00ed p\u0159enosu na ostatn\u00ed. Posun IgG4 v\u0161ak vede k protil\u00e1tkov\u00e9mu profilu, kter\u00fd je pro prevenci infekce a p\u0159enosu \u0161patn\u011b vhodn\u00fd. A k tomuto posunu doch\u00e1z\u00ed ji\u017e po dvou standardn\u00edch d\u00e1vk\u00e1ch u d\u011bt\u00ed, a to je\u0161t\u011b p\u0159ed pod\u00e1n\u00edm posilovac\u00ed d\u00e1vky.<\/span><\/p>\n

\u010cl\u00e1nek tvrd\u00ed, \u017ee pediat\u0159i by m\u011bli pova\u017eovat ot\u00e1zku pokra\u010duj\u00edc\u00edho posilovac\u00edho o\u010dkov\u00e1n\u00ed zdrav\u00fdch d\u011bt\u00ed za klinicko-etick\u00fd probl\u00e9m, nikoli za byrokratick\u00fd. Tyto ne\u017e\u00e1douc\u00ed imunitn\u00ed ud\u00e1losti jsou vnucov\u00e1ny jedinc\u016fm, u kter\u00fdch prakticky neexistuje \u017e\u00e1dn\u00e9 riziko prevence onemocn\u011bn\u00ed, ani\u017e by oni nebo jejich rodiny m\u011bly d\u016fkladn\u00e9 pochopen\u00ed toho, co se s jejich imunitn\u00edm syst\u00e9mem d\u011bje.<\/span><\/p>\n

Pro\u010d v\u00e1m o tom v\u00e1\u0161 krevn\u00ed test nic ne\u0159ekne<\/span><\/strong><\/h3>\n

Standardn\u00ed krevn\u00ed testy po o\u010dkov\u00e1n\u00ed m\u011b\u0159\u00ed celkov\u00fd IgG protil\u00e1tek proti spike. Tato hodnota se zvy\u0161uje po ka\u017ed\u00e9 posiluj\u00edc\u00ed d\u00e1vce. Regula\u010dn\u00ed org\u00e1ny a l\u00e9ka\u0159i ji pou\u017e\u00edvaj\u00ed jako prim\u00e1rn\u00ed m\u011b\u0159\u00edtko \u00fa\u010dinku vakc\u00edny.<\/span><\/p>\n

Celkov\u00fd titr IgG nerozli\u0161uje mezi IgG1, IgG2, IgG3 a IgG4. Vysok\u00e1 hodnota by mohla znamenat, \u017ee m\u00e1te silnou ochrannou imunitu, v n\u00ed\u017e dominuj\u00ed IgG1 a IgG3. M\u016f\u017ee to v\u0161ak tak\u00e9 znamenat, \u017ee m\u00e1te vysok\u00e9 hladiny protil\u00e1tek, z nich\u017e v\u00fdznamnou \u010d\u00e1st tvo\u0159\u00ed IgG4, kter\u00e9 proto nemohou vykon\u00e1vat ADCC, nemohou aktivovat syst\u00e9m komplementu a negativn\u011b koreluj\u00ed s p\u0159esn\u011b t\u011bmi neutraliza\u010dn\u00edmi titry, kter\u00e9 maj\u00ed m\u011b\u0159it.<\/span><\/p>\n

Pacienti, kte\u0159\u00ed dostali \u010dty\u0159i nebo p\u011bt posilovac\u00edch d\u00e1vek a jejich\u017e hladiny protil\u00e1tek byly testov\u00e1ny, nemohou sv\u016fj stav ur\u010dit pouze na z\u00e1klad\u011b tohoto testu. Ani jejich l\u00e9ka\u0159i to nemohou. Standardn\u00ed test je struktur\u00e1ln\u011b slep\u00fd v\u016f\u010di prim\u00e1rn\u00ed ne\u017e\u00e1douc\u00ed ud\u00e1losti.<\/span><\/p>\n

Vysok\u00e1 hladina protil\u00e1tek po n\u011bkolika posilovac\u00edch d\u00e1vk\u00e1ch m\u016f\u017ee znamenat ochranu. M\u016f\u017ee v\u0161ak tak\u00e9 znamenat rostouc\u00ed pod\u00edl toleran\u010dn\u00edch protil\u00e1tek, kter\u00e9 aktivn\u011b br\u00e1n\u00ed schopnosti t\u011bla bojovat s infekc\u00ed. Test nedok\u00e1\u017ee ur\u010dit, kter\u00fd z t\u011bchto p\u0159\u00edpad\u016f je pravdou.<\/span><\/em><\/p>\n

Co je t\u0159eba zm\u011bnit?<\/span><\/strong><\/h3>\n
\"\"<\/figure>\n

Doporu\u010den\u00ed zalo\u017een\u00e1 na t\u00e9to anal\u00fdze jsou jasn\u00e1, i kdy\u017e \u017e\u00e1dn\u00e9 z nich v sou\u010dasnosti nen\u00ed b\u011b\u017enou prax\u00ed.<\/span><\/p>\n

\u2022\u00a0<\/span>Minim\u00e1ln\u00ed interval jednoho roku mezi posilovac\u00edmi o\u010dkov\u00e1n\u00edmi.<\/span><\/strong>\u00a0Tento minim\u00e1ln\u00ed interval sni\u017euje indukci IgG4, proto\u017ee imunitn\u00ed odpov\u011b\u010f m\u016f\u017ee p\u0159ed op\u011btovnou expozic\u00ed zcela odezn\u00edt. \u010cast\u011bj\u0161\u00ed posilovac\u00ed o\u010dkov\u00e1n\u00ed by m\u011blo b\u00fdt pova\u017eov\u00e1no za zn\u00e1m\u00e9 nev\u00fdhody, kter\u00e9 je t\u0159eba explicitn\u011b zv\u00e1\u017eit oproti p\u0159\u00ednos\u016fm.<\/span><\/p>\n

\u2022\u00a0<\/span>Testujte na podt\u0159\u00eddy IgG, nejen na celkov\u00e9 IgG.<\/span><\/strong>\u00a0Celkov\u00e9 titry protil\u00e1tek nemohou odhalit prim\u00e1rn\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinek. Testov\u00e1n\u00ed na podt\u0159\u00eddy IgG by m\u011blo b\u00fdt standardn\u00ed prax\u00ed v klinick\u00fdch studi\u00edch, vy\u017eadov\u00e1no regula\u010dn\u00edmi org\u00e1ny p\u0159ed schv\u00e1len\u00edm dal\u0161\u00edch posilovac\u00edch o\u010dkov\u00e1n\u00ed a dostupn\u00e9 pacient\u016fm, kte\u0159\u00ed podstoupili v\u00edce posilovac\u00edch o\u010dkov\u00e1n\u00ed a cht\u011bj\u00ed v\u011bd\u011bt, jak\u00fd typ protil\u00e1tkov\u00e9 odpov\u011bdi skute\u010dn\u011b maj\u00ed.<\/span><\/p>\n

\u2022\u00a0<\/span>Pou\u017e\u00edvejte absolutn\u00ed, nikoli relativn\u00ed \u00fadaje o riziku.<\/span><\/strong>\u00a0Pacienti maj\u00ed pr\u00e1vo v\u011bd\u011bt, o kolik p\u0159eo\u010dkov\u00e1n\u00ed skute\u010dn\u011b sni\u017euje jejich absolutn\u00ed riziko infekce, a ne jen o jak\u00e9 procento se situace zlep\u0161uje ve srovn\u00e1n\u00ed s nedefinovan\u00fdm v\u00fdchoz\u00edm stavem. \u00dadaje o relativn\u00edm riziku bez absolutn\u00edho kontextu zp\u016fsobuj\u00ed, \u017ee se mal\u00e9 p\u0159\u00ednosy jev\u00ed jako velk\u00e9 a br\u00e1n\u00ed smyslupln\u00e9mu posouzen\u00ed p\u0159\u00ednos\u016f a \u0161kod.<\/span><\/p>\n

\u2022\u00a0<\/span>Zrevidujte pokyny pro posilovac\u00ed o\u010dkov\u00e1n\u00ed d\u011bt\u00ed s ohledem na nov\u00e1 data.<\/span><\/strong>\u00a0Pokyny pro posilovac\u00ed o\u010dkov\u00e1n\u00ed d\u011bt\u00ed by nem\u011bly b\u00fdt odvozeny sn\u00ed\u017een\u00edm doporu\u010den\u00ed pro vysoce rizikov\u00e9 dosp\u011bl\u00e9. D\u011bti pot\u0159ebuj\u00ed vlastn\u00ed d\u016fkazn\u00ed z\u00e1kladnu, kter\u00e1 m\u011b\u0159\u00ed v\u00fdsledky pro podt\u0159\u00eddy IgG, ne\u017e se pokra\u010dov\u00e1n\u00ed v posilovac\u00edm o\u010dkov\u00e1n\u00ed doporu\u010d\u00ed jako standardn\u00ed p\u00e9\u010de.<\/span><\/p>\n

\u2022\u00a0<\/span>Zah\u00e1jit sledov\u00e1n\u00ed, kter\u00e9 m\u011blo za\u010d\u00edt ji\u017e p\u0159ed lety.<\/span><\/strong>\u00a0Minim\u00e1ln\u011b: prospektivn\u00ed studie pro m\u011b\u0159en\u00ed v\u00fdsledk\u016f l\u00e9\u010dby COVID-19 na z\u00e1klad\u011b slo\u017een\u00ed podt\u0159\u00edd IgG; p\u0159ehled p\u0159\u00edpad\u016f onemocn\u011bn\u00ed asociovan\u00fdch s IgG4 v souvislosti s o\u010dkov\u00e1n\u00edm; studie v\u00fdsledk\u016f u pacient\u016f s rakovinou podstupuj\u00edc\u00edch terapii z\u00e1vislou na ADCC, kte\u0159\u00ed tak\u00e9 dostali posiluj\u00edc\u00ed d\u00e1vku; a dlouhodob\u00e9 imunologick\u00e9 sledov\u00e1n\u00ed u d\u011bt\u00ed.<\/span><\/p>\n

\u2022\u00a0<\/span>L\u00e9ka\u0159i mus\u00ed tyto skute\u010dnosti zve\u0159ejnit.<\/span><\/strong>\u00a0Pacienti, kte\u0159\u00ed podstoupili n\u011bkolik posilovac\u00edch d\u00e1vek s p\u0159edpokladem, \u017ee v\u00edce je v\u017edy l\u00e9pe, si zaslou\u017e\u00ed p\u0159esn\u00e9 vysv\u011btlen\u00ed toho, co nyn\u00ed ukazuj\u00ed imunologick\u00e9 n\u00e1lezy. To je to, co znamen\u00e1 informovan\u00fd souhlas.<\/span><\/p>\n

Z\u00e1v\u011br<\/span><\/strong><\/h3>\n

Sou\u010dasn\u00e1 data nazna\u010duj\u00ed, \u017ee mRNA vakc\u00edny proti COVID-19 sni\u017euj\u00ed v\u00fdskyt z\u00e1va\u017en\u00fdch onemocn\u011bn\u00ed a \u00famrt\u00ed u vysoce rizikov\u00fdch pacient\u016f. Zabr\u00e1nily z\u00e1va\u017en\u00fdm onemocn\u011bn\u00edm a \u00famrt\u00edm u mnoha lid\u00ed, kte\u0159\u00ed byli skute\u010dn\u011b ohro\u017eeni. V t\u00e9to anal\u00fdze to nen\u00ed zpochyb\u0148ov\u00e1no. Zda je anal\u00fdza rizik a p\u0159\u00ednos\u016f t\u011bchto produkt\u016f pro danou kohortu pozitivn\u00ed, je zcela jin\u00e1 ot\u00e1zka a tato anal\u00fdza se j\u00ed nezab\u00fdv\u00e1.<\/span><\/p>\n

Je kontroverzn\u00ed, zda jsou opakovan\u00e1 posilovac\u00ed o\u010dkov\u00e1n\u00ed stejn\u011b prosp\u011b\u0161n\u00e1 pro v\u0161echny skupiny obyvatelstva, zda testy protil\u00e1tek pou\u017e\u00edvan\u00e9 k jejich od\u016fvodn\u011bn\u00ed m\u011b\u0159\u00ed to, co je d\u016fle\u017eit\u00e9, a zda lid\u00e9, kte\u0159\u00ed tato posilovac\u00ed o\u010dkov\u00e1n\u00ed dostali, dostali p\u0159esn\u00fd obraz o tom, co se d\u011bje s jejich imunitn\u00edm syst\u00e9mem.<\/span><\/p>\n

Odpov\u011b\u010f na v\u0161echny t\u0159i ot\u00e1zky je \u201ene\u201c. Posun imunity dokumentovan\u00fd v tomto v\u00fdzkumu je skute\u010dn\u00fd, m\u00e1 m\u011b\u0159iteln\u00e9 funk\u010dn\u00ed d\u016fsledky, zesiluje se s ka\u017edou dal\u0161\u00ed posilovac\u00ed d\u00e1vkou, nen\u00ed detekovateln\u00fd standardn\u00edmi testy a jeho dlouhodob\u00e9 \u00fa\u010dinky nejsou zn\u00e1my, proto\u017ee studie pot\u0159ebn\u00e9 k jeho charakterizaci nebyly provedeny.<\/span><\/p>\n

Nic z toho nevy\u017eaduje katastrofick\u00e9 p\u0159edpov\u011bdi ani \u201ekonspira\u010dn\u00ed teorie\u201c. Vy\u017eaduje to v\u0161ak poctivost.<\/span><\/p>\n

Ot\u00e1zkou nen\u00ed, zda vakc\u00edny fungovaly. Ot\u00e1zkou je, zda ch\u00e1peme, co jsme ud\u011blali s imunitn\u00edm syst\u00e9mem milion\u016f lid\u00ed, a zda jsme p\u0159ipraveni to zjistit hned te\u010f.<\/span><\/strong><\/em><\/p>\n

Od Dr. Roberta W. Malona<\/span><\/em><\/p>\n<\/div>\n<\/div>\n

\n
\n

Zdroj<\/span><\/a><\/span><\/h3>\n

 <\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Snadno srozumiteln\u00fd pr\u016fvodce aktu\u00e1ln\u00edmi v\u00fdzkumn\u00fdmi poznatky O co jde Pokud jste podstoupili n\u011bkolik posiluj\u00edc\u00edch d\u00e1vek…<\/p>\n","protected":false},"author":2,"featured_media":103115,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[23,839,651,21],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/103114"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=103114"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/103114\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/103115"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=103114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=103114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=103114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}